About

Race Oncology is focused on improving the lives of cancer patients around the world by…

Science

Bisantrene is a small molecule anthracene-based chemotherapeutic that was originally developed by American Cyanamid (Lederle…

Management team

Find out more about Race Oncology’s board of directors and management team. Board of Directors…

Latest Race Oncology News

+
16 Apr

Race CEO discusses benefits of resurrecting abandoned drugs with Stockhead

Race CEO Dr Daniel Tillett speaks to Nadine McGrath at Stockhead in detail about drug repurposing and resurrecting abandoned or…

08 Apr

WTF with Race Oncology: Changing the chemo game – Stockhead

Race Oncology (ASX:RAC) CEO Dr Daniel Tillett joins Sarah Hughan at the Stockhead’s What The Facts?! video interview series to discuss side effects…

05 Apr

Shareholder Options Q&A

We thank all our shareholders for their strong interest in the Race Oncology Bonus Options and Piggyback Options Offer. We…